Eli Lilly and Co (NYSE:LLY) Stock News, Headlines & Updates
Eli Lilly and Co Stock News from GuruFocus
- 1
- 2
Oct 28, 2024
Lilly declares fourth-quarter 2024 dividend
PRNewswire • 11:00am
Eli Lilly's (LLY) Omvoh Shows Long-term Efficacy for Ulcerative Colitis and Crohn's Disease
GuruFocus News • 8:10am
Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease
PRNewswire • 6:00am
Oct 25, 2024
Eli Lilly's Ebglyss Emerges as New Option for Patients Struggling with Dupixent Treatment
Muslim Farooque • 1:11pm
Oct 23, 2024
LLY: Donanemab Rejected by NHS Due to Cost Concerns
GuruFocus News • 9:52am
Oct 21, 2024
Eaton Vance Worldwide Health Sciences Fund Sharpens Focus on Humana Inc in Q3 2024
GuruFocus News • 3:00pm
Oct 17, 2024
Bernstein Initiates Coverage on LLY, GILD, and AMGN with Outperform Ratings
GuruFocus News • 12:30am
Oct 16, 2024
Lilly confirms date and conference call for third-quarter 2024 financial results announcement
PRNewswire • 10:00am
Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies
PRNewswire • 7:00am
Oct 15, 2024
Eli Lilly (LLY) Invests in UK to Study Obesity Drug Impact on Employment
GuruFocus News • 9:50am
Oct 14, 2024
Eli Lilly (LLY) Increases UK Investment for Diabetes and Obesity Treatments
GuruFocus News • 9:31am
Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease
PRNewswire • 6:00am
Oct 11, 2024
Eli Lilly (LLY) Shares Rise Amid Optimism for Zepbound Approval in Japan
GuruFocus News • 11:31am
Eli Lilly Expects Zepbound Approval in Japan by Mid-2025, Eyes Weight-Loss Market
Muslim Farooque • 11:23am
Eli Lilly (LLY) Stock Rises Amid Optimism for Japan Approval of Weight Loss Drug
GuruFocus News • 10:50am
Oct 09, 2024
Q2 2024 Eli Lilly and Co Earnings Call Transcript
GuruFocus News • 1:41pm
Oct 08, 2024
LLY Stock Rises on Congressional Budget Office Report
GuruFocus News • 5:25pm
LLY: Legal Battle Over FDA's Decision on Eli Lilly's Weight Loss Drug
GuruFocus News • 11:10pm
Oct 07, 2024
Concerns Over Muscle Loss with GLP-1 Weight Loss Drugs (LLY, NVO, REGN)
GuruFocus News • 1:10am
Oct 03, 2024
Supply Issues Resolved for Eli Lilly's (LLY) Zepbound and Mounjaro
GuruFocus News • 12:50am
Eli Lilly (LLY) Solves U.S. Shortage of Mounjaro and Zepbound, Plans Major Expansion
GuruFocus News • 7:10pm
Oct 02, 2024
Eli Lilly (LLY) Announces $4.5 Billion Investment in New Indiana Research and Manufacturing Center
GuruFocus Research • 9:10am
Eli Lilly (LLY) Explores New Uses for Weight-loss Drug Zepbound to Prevent Diabetes and Other Conditions
GuruFocus Research • 7:11am
Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials
PRNewswire • 7:00am
Sep 27, 2024
Eli Lilly and Co (LLY) Stock Price Down 3.16% on Sep 27
GuruFocus Research • 11:02am
Sep 25, 2024
New data show Lilly's EBGLYSSâ„¢ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis
PRNewswire • 6:00am
Sep 24, 2024
Lilly's Kisunlaâ„¢ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease
PRNewswire • 6:00am
Sep 13, 2024
FDA Approves Lilly's EBGLYSSâ„¢ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis
PRNewswire • 4:00pm
Sep 12, 2024
Lilly expands manufacturing footprint in Ireland with $1.8 billion investment
PRNewswire • 5:00am
Sep 10, 2024
With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes
PRNewswire • 11:00am
Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes
PRNewswire • 11:00am
Sep 09, 2024
Lilly appoints Lucas Montarce as executive vice president and chief financial officer
PRNewswire • 6:00am
Sep 05, 2024
In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin
PRNewswire • 6:00am
Sep 04, 2024
Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries
PRNewswire • 6:00am
Aug 27, 2024
Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity
PRNewswire • 6:00am
Aug 22, 2024
Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference
PRNewswire • 10:00am
Aug 20, 2024
Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight
PRNewswire • 6:00am
Aug 16, 2024
Lilly announces retirement of Marschall S. Runge from its Board of Directors
PRNewswire • 4:00pm
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
PRNewswire • 8:00am
Aug 13, 2024
Lilly opens state-of-the-art research and development center in the Boston Seaport
PRNewswire • 8:00am
- 1
- 2
Show
Entries
Headlines
Total 0- 1
No recent news